£126.14
1.32% today
London, Nov 06, 01:45 pm CET
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock price

£124.50
-2.76 2.17% 1M
+17.71 16.58% 6M
+22.04 21.51% YTD
+25.50 25.76% 1Y
+24.62 24.65% 3Y
+48.45 63.70% 5Y
+93.30 299.05% 10Y
+112.37 926.25% 20Y
London, Closing price Wed, Nov 05 2025
-0.78 0.62%
ISIN
GB0009895292
Symbol
AZN
Industry

New AI Insights on AstraZeneca Insights AI Insights on AstraZeneca

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
£194.2b
Enterprise Value
£213.9b
Net debt
£19.7b
Cash
£5.4b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
30.6 | 17.4
P/S
4.5 | 4.2
EV/Sales
4.9 | 4.7
EV/FCF
34.1
P/B
5.7
Dividends
DPS
£2.46
Yield 1Y | 5Y
2.0% | 2.5%
Growth 1Y | 5Y
7.8% | 2.4%
Payout 1Y | 3Y
71.2% | 89.2%
Increased
1 Year
Financials (TTM | estimate)
Revenue
£43.3b | £45.9b
EBITDA
£13.6b | £16.5b
EBIT
£10.6b | £14.4b
Net Income
£6.4b | £11.1b
Free Cash Flow
£6.3b
Growth (TTM | estimate)
Revenue
15.0% | 10.8%
EBITDA
27.4% | 30.1%
EBIT
37.0% | 48.5%
Net Income
28.8% | 105.8%
Free Cash Flow
17.5%
Margin (TTM | estimate)
Gross
82.1%
EBITDA
31.3% | 35.9%
EBIT
24.4%
Net
14.7% | 24.2%
Free Cash Flow
14.5%
Financial Health
Equity Ratio
39.2%
Return on Equity
17.3%
ROCE
17.5%
ROIC
14.5%
Debt/Equity
0.7
More
EPS
£4.1
FCF per Share
£4.0
Short interest
-
Employees
94k
Rev per Employee
£440.0k
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

28x Buy
85%
4x Hold
12%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

Buy
85%
Hold
12%
Sell
3%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
43,296 43,296
15% 15%
100%
- Direct Costs 7,761 7,761
16% 16%
18%
35,535 35,535
15% 15%
82%
- Selling and Administrative Expenses 11,967 11,967
2% 2%
28%
- Research and Development Expense 10,103 10,103
20% 20%
23%
13,569 13,569
27% 27%
31%
- Depreciation and Amortization 3,008 3,008
2% 2%
7%
EBIT (Operating Income) EBIT 10,561 10,561
37% 37%
24%
Net Profit 6,356 6,356
29% 29%
15%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Neutral
Business Wire
about one hour ago
CAMBRIDGE, England--(BUSINESS WIRE)--Q3 2025 Results Release.
Positive
Proactive Investors
about 6 hours ago
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted a confident set of third-quarter results, not only beating revenue and core earnings forecasts, but also hailing "strong underlying momentum" across the business to set up growth through next year as well. The FTSE 100 pharmaceutical group generated revenues of $15.19 billion in the three months to 30 September, up 12% compared to a year ago and beat...
Positive
WSJ
about 6 hours ago
The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57 billion.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today